Mar Vista Investment Partners LLC Trims Holdings in Johnson & Johnson (NYSE:JNJ)

Mar Vista Investment Partners LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 16.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 184,786 shares of the company's stock after selling 37,249 shares during the quarter. Johnson & Johnson accounts for 2.5% of Mar Vista Investment Partners LLC's portfolio, making the stock its 22nd biggest holding. Mar Vista Investment Partners LLC's holdings in Johnson & Johnson were worth $30,645,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. MRP Capital Investments LLC boosted its position in Johnson & Johnson by 4.1% during the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after purchasing an additional 65 shares during the period. Syverson Strege & Co boosted its position in shares of Johnson & Johnson by 4.9% in the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock valued at $202,000 after acquiring an additional 65 shares during the period. MBA Advisors LLC boosted its position in shares of Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after acquiring an additional 68 shares during the period. Sovereign Financial Group Inc. boosted its position in shares of Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after acquiring an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc boosted its position in shares of Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after acquiring an additional 69 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 0.9%

Shares of NYSE JNJ traded down $1.44 during mid-day trading on Tuesday, hitting $155.38. The stock had a trading volume of 6,859,049 shares, compared to its average volume of 8,081,487. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The business has a 50 day moving average price of $153.79 and a two-hundred day moving average price of $154.63. The firm has a market cap of $373.86 billion, a P/E ratio of 17.28, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on JNJ. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Royal Bank Of Canada reiterated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Morgan Stanley reiterated an "underperform" rating on shares of Johnson & Johnson in a research report on Thursday, July 10th. Finally, Bank of America dropped their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $171.00.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.